EVGN (Evogene) Total Liabilities: $9.96 Mil (As of Mar. 2026)


EVGN Evogene Ltd EVGN
33 GF Score
Price $0.44
GF Value $0.40
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is Evogene Total Liabilities?

Evogene EVGN +1.70% 33 Total Liabilities is $9.96 Mil as of Mar. 2026. GuruFocus rates EVGN with a GF Score™ of 33/100 and a GF Value™ of $0.40 (Fairly Valued). The stock has 7 warning signs investors should review.

Evogene's Total Liabilities for the quarter that ended in Mar. 2026 was $9.96 Mil.

Evogene's quarterly Total Liabilities declined from Sep. 2025 ($8.83 Mil) to Dec. 2025 ($8.07 Mil) but then increased from Dec. 2025 ($8.07 Mil) to Mar. 2026 ($9.96 Mil).

Evogene's annual Total Liabilities increased from Dec. 2023 ($22.42 Mil) to Dec. 2024 ($25.03 Mil) but then declined from Dec. 2024 ($25.03 Mil) to Dec. 2025 ($8.07 Mil).

Evogene Total Liabilities Historical Data

* Premium members only.

The historical data trend for Evogene's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evogene Total Liabilities Chart

Evogene Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.88 21.34 22.42 25.03 8.07

Evogene Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.91 21.55 8.83 8.07 9.96
EVGN
33GF Score
Evogene Ltd EVGN
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Evogene Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Evogene's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=3.444+(1.482+-4.4408920985006E-16
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+3.145+0+0)
=8.07

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=20.046-11.975
=8.07

Evogene's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=5.364+(1.377+4.4408920985006E-16
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+3.217+0+0)
=9.96

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=17.948-7.99
=9.96

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $9.96 Mil mean?
Evogene (EVGN) has a Total Liabilities of $9.96 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Evogene and its competitors.
Is Evogene's Total Liabilities too high?
Evogene's current Total Liabilities is $9.96 Mil. Overall, Evogene has a GF Score™ of 33/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Evogene's Total Liabilities compare to VRTX and REGN?
Evogene's Total Liabilities of $9.96 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Evogene and its competitors. Evogene's current Total Liabilities is $9.96 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evogene stock overvalued right now?
Based on GuruFocus' analysis, Evogene (EVGN) is currently considered Fairly Valued. The stock's GF Value™ is $0.40, compared to a current price of $0.44 — trading 9.3% above its estimated fair value. The current Total Liabilities is $9.96 Mil. Evogene's overall GF Score™ is 33/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Evogene (EVGN), the current Total Liabilities is $9.96 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Evogene (EVGN) Overvalued in 2026?

Based on GuruFocus' analysis, Evogene stock appears to be overvalued. The current stock price of $0.44 is trading 9.3% above its estimated GF Value™ of $0.40. GuruFocus considers Evogene to be Fairly Valued.

Key valuation signals for EVGN:

  • Total Liabilities: $9.96 Mil
  • GF Value™: $0.40 vs. price of $0.44 (9.3% above fair value)
  • GF Score™: 33/100 with 7 warning signs

No single metric tells the full story. See the EVGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Evogene Business Description

Other Exchanges EVGN:Israel
Address 13 Gad Feinstein Street, Park Rehovot, Ness Ziona, Rehovot, ISR, 7638517
Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules, and genetic elements as the core components for such products. It holds several subsidiaries utilizing the CPB platform for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits, and ag-solutions for castor oil production. It generates maximum revenue from the industrial segment, followed by Agriculture.
33GF Score

Get the complete analysis for EVGN

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.44
Price
$0.40
GF Value